Finch Therapeutics Group Inc 's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Finch Therapeutics Group Inc 's ROA in the second quarter of 2024?
Finch Therapeutics Group Inc recorded a cumulative net loss of $-13 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -24.48%.

However, within the Healthcare sector 408 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2024 quarter, so far to 3799, from total ROA ranking in the first quarter of 2024 at 3885.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Total Assets Change	-32.88 %	-37.25 %	-57.96 %	-61.95 %	-66.56 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-13	-15	-73	-99	-137
Return On Assets (TTM)	-24.48 %	-25.89 %	-114.37 %	-119.33 %	-128.26 %
FNCH's Total Ranking	# 3799	# 3885	# 5521	# 4953	# 5066
Total Assets (TTM) in million	44	49	54	59	65
Seq. Total Assets Change	-10.14 %	-10.5 %	-7.03 %	-10.23 %	-15.99 %
Seq. Net Income Change	-	-	-	-	-

FNCH's 5 Years Annual ROA >> Back to FNCH Management Effectiveness >> Compare FNCH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 46
Sector	# 409
Overall	# 3737

Return On Assets Statistics
High	Average	Low
-23.87 %	-60.77 %	-112.23 %
(Dec 31 2021)		(Dec 31 2023)

Financial Statements
Finch Therapeutics Group Inc 's Assets	$ 44 million	FNCH's Balance sheet
Finch Therapeutics Group Inc 's Income	$ -5 million	Quarterly FNCH's Income Statement
FNCH's Income by Division		See FNCH's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY	FY
Y / Y Total Assets Change	-57.96 %	-32.64 %	-	-	-
Total Assets in million	54	129	192	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-75	-115	-58	0	0
Annual Return On Assets	-137.31 %	-88.54 %	-30.25 %	-	-

FNCH's 5 Years Annual ROA >> Back to FNCH Management Effectiveness >> Compare FNCH ROA to its Competitors

More Return On Assets Ratios
FNCH's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FNCH's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FNCH's Competitors
Subscribers only: Roa for Finch Therapeutics Group Inc 's Suppliers
Subscribers only: Return On Assets for FNCH's Customers

You may also want to know
FNCH's Roi	FNCH's Inventory Turnover Ratio	FNCH's Growth Rates	FNCH's Dividend Comparisons
	FNCH's Profitability Ratios	FNCH's Asset Turnover Ratio	FNCH's Dividend Growth
FNCH's Roe	FNCH's Valuation Ratios	FNCH's Financial Strength Ratios	FNCH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-06-22T16:30:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.